CSL (CSJA) Q4 2026 Earnings Report

The call presents a mixed picture: operational and commercial turnaround actions are beginning to show early, tangible benefits (strong cash flow, successful transformation savings, Seqirus market outperformance, Ig momentum and promising product launches), but these positives are offset by very large impairments, significant and structural headwinds in Vifor (expected ~25% revenue decline in FY'27), continued albumin pricing pressure in China and an FY'26 statutory loss driven by noncash charges. Management’s FY'27 underlying guidance (NPAT +~5% cc; Behring growth) and capital returns indicate confidence in a return to profitable growth, yet the scale of recent impairments and the outlook for Vifor mean near-term headwinds remain material.

CSL guided FY '27 group revenue to be broadly in line with FY '26 (FY '26 revenue $15.8bn, -1% cc) and expects underlying NPAT (excluding restructuring and impairments) to grow by approximately 5% at constant currency (noting an estimated FX headwind of about $50m at current rates). By business, CSL Behring is expected to deliver mid‑single‑digit revenue growth with immunoglobulin growing mid‑ to high‑single digits and a modest gross‑margin improvement, Seqirus low‑single‑digit revenue growth, and CSL Vifor a ~25% revenue decline (no TAVNEOS sales included in guidance). The transformation program should deliver ~ $220m incremental savings in FY '27 (building on $176m delivered in FY '26) taking annualized savings to ~ $400m and up to $550m in FY '28, with roughly half the incremental savings to be reinvested; FY '27 CapEx is expected to be about $1.0bn ± $100m. Capital return and balance‑sheet items include a new share buyback of ~AUD 1.1bn, the dividend maintained in US$ (FY '26 full‑year $2.92 per share, final $1.62), and a target net‑debt/EBITDA range of 1.5–2x.